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Since the inception of the model for end-stage liver disease
(MELD) liver transplant allocation system in 2002, it has
been recognized that some diseases exist for which mor-
tality risk is not adequately measured by MELD score. For
this reason patients with hepatocellular carcinoma (HCC)
have been assigned an exception MELD score. In this is-
sue of AJT (1), Washburn and colleagues attempted to
determine whether the current exception score results in
an unfair advantage for HCC patients. They used com-
peting risk methods to compare rates of dropout from
the waiting list between adults who received an excep-
tion for HCC, versus those without HCC who were listed
with their laboratory MELD score. They found that HCC
patients have substantially lower dropout rates than non-
HCC patients: 12% versus 18% at 1 year after listing.
The authors also analyzed factors independently associ-
ated with dropout among HCC patients, which included
tumor size, laboratory MELD score and level of alpha-
fetoprotein.
In considering the policy implications of these findings, we
must first ask which is the most relevant comparison to
make. Currently patients with HCC receive an initial prior-
ity score of 22, which is upgraded to 25 after 3 months.
Therefore, based upon an ethical allocation framework of
‘sickest first’, HCC patients would be receiving unfair prior-
ity if their 6-month dropout rates were lower than non-HCC
patients having MELD scores of 22–25. Although this ex-
act comparison was not reported by Washburn et al., the
fact that dropout rates for patients with MELD <21 were
higher than rates for HCC patients suggests that HCC
patients are indeed unfairly advantaged. This conclusion
is also supported by evidence that HCC patients receive
higher quality organs than non-HCC patients (2), suggest-
ing that HCC patients can afford to turn down marginal or-
gans because of their high-priority status for future organ
offers.
If the current priority for HCC is unfairly high, then how
should it be adjusted? The easiest approach would be
to simply reduce the initial priority score awarded from
22 points down to 18 or 20 points. However, this approach
would ignore the fact that HCC patients are a heteroge-
neous group with varying tumor biology and degree of
underlying liver dysfunction. A continuous priority score
such as proposed by Washburn et al. is conceptually ap-
pealing for several reasons. In keeping with the Final Rule,
a continuous priority score could potentially reduce wait-
ing list mortality by transplanting patients at higher risk of
disease progression. It would eliminate the incentive to list
patients quickly in order to accrue waiting time, thus poten-
tially selecting out some patients with poor tumor biology.
Finally, a continuous priority score might encourage the
use of alternative treatment modalities such as resection
or radiofrequency ablation for patients with small tumors
and preserved liver function.
Despite these theoretical advantages, it is unclear how
such a continuous scoring system would function in actual
practice. First, the unfortunate reality is that factors such
as tumor size, MELD score and level of alpha-fetoprotein,
which predict dropout from the waiting list, also predict
worse outcomes posttransplant (3). In particular, HCC pa-
tients with high MELD scores likely represent two groups:
(1) those with advanced liver disease that limits ablative
therapies but who would do well with transplant, and (2)
those with infiltrating HCC and unfavorable tumor biology,
whose tumor burden is greater than appreciated on cross-
sectional imaging. An ideal prognostic system would be
able to discriminate between these types of patients in or-
der to measure survival benefit from liver transplantation.
Despite effort by many investigators, such a prognostic
system has yet to be well validated. Second, the proposed
continuous score represents one snapshot in time, and
does not reflect the dynamic nature of HCC. How would
such a score incorporate change in imaging characteristics
after loco-regional therapies, and would this actually create
a disincentive to use such therapies? Or would the Milan
criteria still play the role of a ceiling? Finally, the proposed
continuous score does not address the prominent dispar-
ities in organ availability between regions of the country
(4). Although limited by sample size, Figure 1 of the paper
by Washburn et al. suggests that reduction in priority for
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HCC at the national level might actually disadvantage HCC
patients in some regions such as 5 and 7. Discussion of ge-
ographic variation in organ availability is beyond the scope
of this editorial, except to point out that such disparities are
more pronounced than those between HCC and non-HCC
patients.
In summary, the study by Washburn et al. adds to a growing
body of literature indicating that the current priority score
provides HCC patients an unfair advantage in organ alloca-
tion. The authors have identified an important problem, for
which the ideal solution remains unsolved. Further work is
needed to develop and validate a scoring system, which
accurately and reproducibly predicts the survival benefit of
liver transplantation for HCC.
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